Literature DB >> 17350369

Microbiological profile of septic complication in patients with cardiogenic shock following acute myocardial infarction (from the SHOCK study).

Shun Kohsaka1, Venu Menon, Kentaro Iwata, April Lowe, Lynn A Sleeper, Judith S Hochman.   

Abstract

We sought to assess the microbiologic profile of patients with suspected sepsis who participated in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? (SHOCK) trial, a randomized controlled trial of early coronary revascularization in patients with cardiogenic shock complicating acute myocardial infarction. A protocol-mandated SEPSIS form was completed prospectively for 54 patients (18%) with fever or leukocytosis suggestive of sepsis. These patients were divided further into those with positive (n = 40) or negative (n = 14) culture results. The predominant pathogen isolated in patients with positive culture results was Staphylococcus aureus (32%), followed by Klebsiella pneumoniae and Pseudomonas aeruginosa. Patients with both positive and negative culture results had longer median durations of mechanical ventilation (p <0.001 and p = 0.02), intra-aortic balloon pump (IABP) support (p = 0.074 and p = 0.021), and hospital stay (p <0.001 and p = 0.048) than controls. Sepsis was predicted by both duration of IABP support (p = 0.007) and use of multiple central catheters (p = 0.026). In conclusion, clinical sepsis is common after cardiogenic shock complicating acute myocardial infarction, particularly in patients who received prolonged IABP support or had multiple central catheters.

Entities:  

Mesh:

Year:  2007        PMID: 17350369     DOI: 10.1016/j.amjcard.2006.10.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock.

Authors:  Roland Prondzinsky; Susanne Unverzagt; Henning Lemm; Nikolas-Arne Wegener; Axel Schlitt; Konstantin M Heinroth; Sebastian Dietz; Ute Buerke; Patrick Kellner; Harald Loppnow; Martin G Fiedler; Joachim Thiery; Karl Werdan; Michael Buerke
Journal:  Clin Res Cardiol       Date:  2012-01-03       Impact factor: 5.460

2.  Evidence-based Management of Cardiogenic Shock After Acute Myocardial Infarction.

Authors:  Karl Werdan; Martin Russ; Michael Buerke; Roland Prondzinsky; Sebastian Dietz
Journal:  Interv Cardiol       Date:  2013-08

3.  Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study.

Authors:  Jiri Parenica; Jiri Jarkovsky; Jan Malaska; Alexandre Mebazaa; Jana Gottwaldova; Katerina Helanova; Jiri Litzman; Milan Dastych; Josef Tomandl; Jindrich Spinar; Ludmila Dostalova; Petr Lokaj; Marie Tomandlova; Monika Goldergova Pavkova; Pavel Sevcik; Matthieu Legrand
Journal:  Shock       Date:  2017-02       Impact factor: 3.454

4.  Study of risk factors for healthcare-associated infections in acute cardiac patients using categorical principal component analysis (CATPCA).

Authors:  Emilio Renes Carreño; Almudena Escribá Bárcena; Mercedes Catalán González; Francisco Álvarez Lerma; Mercedes Palomar Martínez; Xavier Nuvials Casals; Felisa Jaén Herreros; Juan Carlos Montejo González
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

Review 5.  Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature.

Authors:  Razvan I Radu; Tuvia Ben Gal; Magdy Abdelhamid; Elena-Laura Antohi; Marianna Adamo; Andrew P Ambrosy; Oliviana Geavlete; Yuri Lopatin; Alexander Lyon; Oscar Miro; Marco Metra; John Parissis; Sean P Collins; Stefan D Anker; Ovidiu Chioncel
Journal:  ESC Heart Fail       Date:  2021-10-19

Review 6.  Heart rate and diastolic arterial pressure in cardiac arrest patients: A nationwide, multicenter prospective registry.

Authors:  Chul Han; Jae Hoon Lee
Journal:  PLoS One       Date:  2022-09-14       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.